Clonal architecture of secondary acute myeloid leukemia.
Walter, Matthew J; Shen, Dong; Ding, Li; Shao, Jin; Koboldt, Daniel C; Chen, Ken; Larson, David E; McLellan, Michael D; Dooling, David; Abbott, Rachel; Fulton, Robert; Magrini, Vincent; Schmidt, Heather; Kalicki-Veizer, Joelle; O'Laughlin, Michelle; Fan, Xian; Grillot, Marcus; Witowski, Sarah; Heath, Sharon; Frater, John L; Eades, William; Tomasson, Michael; Westervelt, Peter; DiPersio, John F; Link, Daniel C; Mardis, Elaine R; Ley, Timothy J; Wilson, Richard K; Graubert, Timothy A.
N Engl J Med
; 366(12): 1090-8, 2012 Mar 22.
Artigo em Inglês | MEDLINE | ID: mdl-22417201
Mutation Clearance after Transplantation for Myelodysplastic Syndrome.
[Genomic aberrations in myelodysplastic syndromes and related disorders].
Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression.
Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
Enhancer DNA methylation in acute myeloid leukemia and myelodysplastic syndromes.
Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes.
[Mutation analysis of 77 patients with normal-karyotype myelodysplastic syndrome].
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis.
A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.